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http://dx.doi.org/10Chronic granulomatous disease (CGD) is a rare genetic disease characterized by severe and
persistent childhood infections. It is caused by the lack of an antipathogen oxidative burst,
normally performed by phagocytic cells to contain and clear bacterial and fungal growth.
Restoration of immune function can be achieved with heterologous bone marrow transplan-
tation; however, autologous bone marrow transplantation would be a preferable option.
Thus, a method is required to recapitulate the function of the diseased gene within the
patient’s own cells. Gene therapy approaches for CGD have employed randomly integrating
viruses with concomitant issues of insertional mutagenesis, inaccurate gene dosage, and gene
silencing. Here, we explore the potential of the recently described clustered regularly inter-
spaced short palindromic repeat (CRISPR)-Cas9 site-specific nuclease system to encourage
repair of the endogenous gene by enhancing the levels of homologous recombination. Using
induced pluripotent stem cells derived from a CGD patient containing a single intronic
mutation in the CYBB gene, we show that footprintless gene editing is a viable option to
correct disease mutations. Gene correction results in restoration of oxidative burst function
in iPS-derived phagocytes by reintroduction of a previously skipped exon in the cytochrome
b-245 heavy chain (CYBB) protein. This study provides proof-of-principle for a gene therapy
approach to CGD treatment using CRISPR-Cas9. Copyright  2015 ISEH - International
Society for Experimental Hematology. Published by Elsevier Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).The advent of site-specific nucleases has stimulated much
excitement for their potential to spawn a new era of
in vitro experimental human genetics, in a similar vein to
the impact of transgenic mice in the 1980s. Site-specific
nucleases also have great potential as therapeutic tools, in
theory capable of elevating homologous recombination in
human cells to a level that could truly provide a personal-
ized curative gene therapy option for genetic diseases
[1,2]. Here, we investigate the site-specific clustered regu-
larly interspaced short palindromic repeat (CRISPR)-Cas9
system for correction of a point mutation in the CYBB
gene that results in chronic granulomatous disease (CGD).: Dr. Michael D. Moore, Sir William Dunn School of
of Oxford, South Parks Road, Oxford OX13RE,
ail: kenny.moore@path.ox.ac.uk
related to this article can be found online at http://
exphem.2015.06.002.
 2015 ISEH - International Society for Experimental Hem
//creativecommons.org/licenses/by/4.0/).
.1016/j.exphem.2015.06.002CGD, a disease characterized by recurrent, severe bacte-
rial and fungal infections, results from an inability of
phagocytic cells, particularly the innate immune sentinels
macrophages and neutrophils, to generate an oxidative burst
upon recognition of an invading pathogen [3]. This oxida-
tive burst generates various reactive oxygen species
(ROS), such as hydrogen peroxide, that are able to
neutralize the pathogen, thereby aiding in clearance and
preventing its continued spread. Although antibiotic treat-
ment options exist for CGD, they are not optimal, since
there is a lifelong dependency, and the only curative ther-
apy involves heterologous bone marrow transplantation,
which has its own inherent risks. Human leukocyte antigen
(HLA)-identical donors outside siblings are also extremely
rare. An alternative treatment option, gene therapy using
autologous bone marrow transplantation of hematopoietic
stem cells modified with retroviral vectors to express a
wild-type (WT) copy of the mutated gene, has been attemp-
ted in clinical trials, with initial curative success [4].atology. Published by Elsevier Inc. This is an open access article under the
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and complications arose due to insertional mutagenesis
resulting in myelodysplasia [5]. This demonstrates the
potential for success but also the need for a cleaner system
to perfectly genetically correct the diseased genome.
Homologous recombination as an experimental tool has
historically been an inefficient process, the use of which
has been constrained to a limited range of model organisms
(notably bacteria, yeast, trypanosomes, and transgenic mice
[6–8]). The development of site-specific nucleases, such as
that based on the bacterial adaptive antiviral immune sys-
tem, CRISPR-Cas9 [9], have been key in expanding the
use of homologous recombination in human cells. Creation
of double-strand breaks (DSBs) at the precise location
desired for genetic modification can enhance the efficiency
of homologous recombination to levels that allow both
easy isolation of modified cells and, depending on require-
ment, the use of the cells as a mixed population of modified
and unmodified cells [10].
CGD is a monogenic disease and is a prime candidate
for gene therapy, particularly since bone marrow transplan-
tation is already a treatment option. Although there are a
number of genes involved in the ROS-producing nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase
complex, the mutation of any of which can result in
CGD, the majority of cases (O60%) are due to loss of func-
tion of the cytochrome b-245 heavy chain (CYBB) protein
(or GP91PHOX) [11]. The gene encoding CYBB is located
on the X chromosome and, therefore, is only present as a
single copy in male sufferers. We [12] and others [13]
have previously generated induced pluripotent stem cells
from CGD suffers, the differentiated myeloid descendants
of which recapitulate the ROS defect characteristic of the
disease. Using one of these patient-derived iPS cell lines
(CGD2) with a single point mutation (T O G) at the end
of intron 1 of CYBB [12], we report high levels of gene
correction using CRISPR-Cas9, show recovery of gene
function in differentiated phagocytic progeny cells, and
demonstrate that the T O G mutation results in exon skip-
ping within the mRNA of CYBB.Materials and methods
Cell culture
Cell culture reagents were sourced from Invitrogen unless other-
wise stated. Wild-type human iPS cell lines NHDF1 [14] and
OX1-19 [15], as well as CGD-patient-derived iPS cells CGD1
(iPSC-CGD1.1 containing a frameshift mutation in exon 2 of
the P47PHOX gene) [12] and CGD2 (iPSC-CGD2 containing point
mutation in intron 1 of the CYBB gene) [12], have been character-
ized previously and were collected with informed consent and
ethical approval (REC 10/H0505/71 and Zurich 2010-0077/2,
respectively). IPS cell lines were grown in mTeSR1 on Matrigel
(Corning)-coated tissue culture dishes, passaged using TrypLE,
and plated with the Rho-kinase inhibitor Y-27632 (10 mmol/L;Abcam). 293 and 293T cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS),
100 U/mL penicillin, and 100 mg/mL streptomycin (D10).
Vector construction
The CRISPR-Cas9 vectors used in this study were based on the
dual Cas9-and guide RNA (gRNA)-expressing, pX330 plasmid,
the Cas9D10A-expressing-derivative, pX335, and its puromycin-
resistance gene-expressing derivative, pX462 [16] (gifts from
Feng Zhang; Addgene plasmids #42230, #42335, and #48141).
Cloning was performed as previously described [16] using oligo-
nucleotides Crisprgp912f (CACCGAAACTTCATGCAATTATTT)
and Crisprgp912r (AAACAAATAATTGCATGAAGTTTC) with
pX335 to create pX335-gp912; oligonucleotides Crisprgp913f
(CACCGCAGTAGATTCCACACAAGAC) and Crisprgp913r
(AAACGTCTTGTGTGGAATCTACTGC) with pX462 to create
pX462-gp913; and oligonucleotides RF178 (CACCGTCGTGCTG
CTTCATGTGGT) and RF179 (AAACACCACATGAAGCAGCA
CGAC) with pX462 to create pX462-g27. The blue fluorescent
protein (BFP)-expressing vector (pHR’SIN-cPPT-EF1-BIP) was
created by site-directed mutagenesis of the eGFP gene present
in the original pHR’SIN-cPPT-EF1-GIP (a derivative of
pHR’SIN-cPPT-SE [17], but containing enhanced green fluores-
cent protein [eGFP] and puromycin resistance gene expressed
from an internal EF1a promoter), using primers pGChismut5
(CACCTGAGCCACGGCGTGCAGTGCTT) and pGChismut6
(GCACGCCGTGGCTCAAGGTGGTCACGAG). The gene-
editing donor vectors were constructed using standard TOPO clon-
ing (Invitrogen) of polymerase chain reaction (PCR)-amplified
product of genomic DNA from OX1-19 cells using CYBB-
specific primers (forward GAATGGAATATGAATGGAGCTTT
TG, reverse CCTGTATCCATCCATCAACTCATCT) to create
pTOPO-gp91, as well as pHR’SIN-cPPT-EF1-GIP using specific
primers (forward GGGGAGAACCGTATATAAGTGCAG, reverse
GCCTAGACGTTTTTTAACCTCGACT) to create pTOPO-GFP
(WT Plasmid). Site-directed mutagenesis using primers RF180
(CAGCCGCTACCCGGACCACATGAAG) and RF181 (CTTC
ATGTGGTCCGGGTAGCGGCTG) was performed on pTOPO-
GFP to remove the protospacer-adjacent motif (PAM) of gRNA-
27 and create Mut plasmid. All vectors were sequenced to ensure
sequence integrity.
Lentiviral transduction and transfection
Vesicular stomatitis virus G protein (VSV-g) pseudotyped lentivi-
ral vectors, generated in 293T cells using pHR’SIN-cPPT-EF1-
BIP, pCMV-deltaR8.2, and pMD2.G (gifts from Didier Trono;
Addgene plasmids #12263 and #12259), were used to transduce
OX1-19 and 293 cells at low multiplicity of infection (MOI;
0.15), to ensure only a single integrant per cell. Following puro-
mycin selection, the resulting OX1-19.BIP and 293.BIP cell lines
were used to quantify gene-editing frequencies by transfection.
DNA transfection of 293.BIP cells was performed using
TurboFect (ThermoScientific) according to the manufacturer’s
protocol. Briefly, 4  105 cells plated the day before transfection
were transfected with 1 mg total DNA (0.35 mg pX462-g27,
0.35 mg WT or Mut plasmid, and 0.4 mg pCAG-dsRED [a gift
from Connie Cepko; Addgene plasmid # 11151] [18]). Three
days posttransfection, the cells were harvested for quantification
of transfection efficiency by flow cytometry for dsRED expression
and replated for another 2 days; then eGFP expression was
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fected in a single-cell suspension by electroporation (neon trans-
fection platform, Invitrogen), using 2  105 cells in a 10 mL tip
with 1 mg total DNA (0.5 mg pX462-g27 plasmid and 0.5 mg
WT or Mut plasmid). For ssODN transfections, 1 mg total DNA
was transfected (0.5 mg pX462-g27 plasmid and 0.5 mg ssODN)
using WT ssODN (GTCGTCCTTGAAGAAGATGGTGCGCTC
CTGGACGTAGCCTTCGGGCATGGCGGACTTGAAGAAGTC
GTGCTGCTTCATGTGGTCGGGGTAGCGGCTGAAGCACTG
CACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGG
GCACGGGCAGCTTGCCG) and Mut ssODN (GTCGTCCT
TGAAGAAGATGGTGCGCTCCTGGACGTAGCCTTCGGGCA
TGGCGGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCCG
GGTAGCGGCTGAAGCACTGCACGCCGTAGGTCAGGGTGG
TCACGAGGGTGGGCCAGGGCACGGGCAGCTTGCCG). After
one pulse of electroporation at 1400 volts, 20 msec pulse width,
the cells were plated onto Matrigel in mTeSR1 containing
10 mmol/L Y-27632 without penicillin/streptomycin. Five days
posttransfection, the cells were assayed for eGFP expression by
flow cytometry.
Gene editing and single-cell cloning
For gene editing at the CYBB locus, 1  106 CGD2 iPS cells were
transfected by electroporation (1000 volts, 40 msec pulse width,
one pulse) in a 100 mL tip with 10 mg total DNA (2.5 mg
pTOPO-gp91, 3.75 mg pX335-gp91.2, 3.75 mg pX462-gp91.3).
After electroporation, the cells were plated at high density
(5  105 cells/cm2) for 24 hours before passaging into lower den-
sity with the addition of 1 mg/mL puromycin. Twenty-four hours
later, the selection was removed, and surviving cells (GC16A)
were assayed for gene-editing frequency by sequencing the
CYBB locus using PCR primers gp91forward1 (GGTATACTGGC
CAAATCATA) and gp91reverse4 (AATTGTTGGAGTGAGAGT
CAA). The GC16 cell line was plated at low density onto
mitotically-inactivated mouse embryonic feeder (MEF; outbred
Swiss mice established and maintained at the Department of
Pathology, Oxford [19,20]) cells on gelatin-coated tissue culture
plates in hESC medium (KO-DMEM, 2 mmol/L L-Glutamine,
100 mmol/L nonessential amino acids, 20% serum replacement,
and 8 ng/mL basic fibroblastic growth factor (FGF2)). Colonies
were manually selected, sequenced using CYBB-specific PCR
primers gp91forward1 and gp91reverse2 (CAGGAAGTTG
CAATGGAGGGA), and converted to growth on Matrigel in
mTeSR1.
Monocyte/macrophage differentiation and ROS activity
Production of monocytes and macrophages from iPS cells has
been described previously [15]. Monocytes released from the fac-
tories were either used directly, adhered to tissue-culture plates for
24 hours, or differentiated into macrophages on tissue culture
plates in XVIVO 15 supplemented with GlutaMAX and
100 ng/mL macrophage-colony stimulating factor (M-CSF),
before analysis for ROS production. Nitroblue tetrazolium
(NBT), dihydrorhodamine (DHR), and luminol assays were used
to identify ROS activity from monocytes and macrophages, as pre-
viously described [12], after stimulation with 500 ng/mL phorbol
12-myristate 13-acetate (PMA; 200 ng/mL for the luminol assay)
or 500 ng/mL PMA and 0.5 mmol/L formyl-methionyl-leucyl-
phenylalanine (fMLP), respectively.Quantitative real-time PCR (qRT-PCR)
The level of CYBB mRNA was quantified using two different
primer pairs, compared with the level of the endogenous control,
b-Actin (Eurogentec), and expressed as relative quantities
compared with the WT cell line using the DDCT method [21].
Primers used included gp91 exon 1 forward (CAACACATTCA
ACCTCTGCC), gp91 exon 3 reverse (GGACAGCAGATTTCGA
CAG), gp91 exon1-2 boundary forward (TTTTGTCATTCTGGT
TTGGCTG), and gp91 exon 2-3 boundary reverse (CCAGTGCT
GACCCAAGAAGT). Reactions were carried out in triplicate on
an ABI StepOne Plus qPCR machine using SensiMix SYBR re-
agent (Bioline).Results
CRISPR-Cas9 system has the potential to perform gene
editing at clinically relevant levels for CGD
The frequency of cells with a functional NADPH oxidase
complex required to relieve CGD sufferers’ symptoms is
estimated to be only 10% of circulating monocytes and neu-
trophils [22–24]. Thus, we set out to establish if such levels
of gene editing were possible using a model system for ac-
curate quantification of homologous recombination rates.
The model consisted of cell lines (either HEK293 or
OX1-19 iPS cells) transduced by a lentiviral vector express-
ing a BFP that differs from eGFP by two neighboring amino
acid substitutions within the chromophore (S65T and H66Y;
Fig. 1A). After transfection of these cells with a plasmid
expressing Cas9 and a guide RNA (gRNA-27) targeting a
site nearby the BFP/eGFP mutations, along with a repair
template containing a partial WT eGFP sequence, the fluo-
rescent marker switch from BFP to eGFP can be easily
detected and the gene editing frequency quantified by
flow cytometry (Fig. 1B). Using this model, we were able
to show that the CRISPR-Cas9 system is able to achieve
rates of homologous recombination above 10% in both
HEK293 cells and iPS cells (Fig. 1C). This rate of gene ed-
iting (17.0% 6 0.35 for iPS cell and 13.6% 6 1.4 for
HEK293 cells) was only observed when using a plasmid
donor template (Mut plasmid) containing a mutated PAM,
a sequence essential for cleavage by Cas9. In contrast,
without a mutated PAM (WT plasmid) tenfold lower levels
of gene editing were detected (0.77% 6 0.05 for iPS cells
and 1.4%6 0.75 for HEK293 cells). A similar phenomenon
was observed when using single-stranded oligonucleotides
(ssODNs) as donor templates; an ssODN with a mutated
PAM (Mut ssODN) was more efficient than an ssODN
with the WT sequence (WT ssODN; 1.16% 6 0.09 versus
0.16% 6 0.1; p ! 0.001; Fig. 1B). Since the ssODN was
noncomplementary to the gRNA-27 and, therefore, not a
target for cleavage by Cas9, the reduction in gene editing
observed with a WT PAM was likely due to Cas9-
directed cleavage and mutation of the gene after successful
homologous recombination, resulting in loss of the eGFP
signal. Moreover, in our hands the level of gene editing
Figure 1. Fluorescent reporter system for CRISPR-Cas9 activity. (A) Alignment of BFP and eGFP showing the mutations that are required for gene editing
to convert BFP into eGFP (bold), the location of gRNA-27 target site (underlined), and its PAM (overlined). (B) Representative dot plot showing the change
in fluorescence from BFP-expressing cells to eGFP after CRISPR-Cas9 mediated gene editing in iPS cells. (C) Gene-editing efficiency of BFP into eGFP in
HEK 293 cells (black) and OX1-19 iPS cells (grey bars) using gRNA-27 and donor templates, as indicated. Templates included plasmids containing the WT
eGFP sequence (WT plasmid) or a mutated eGFP sequence with the PAM altered to prevent cleavage without altering the amino acid sequence (Mut
plasmid), as well as single-stranded oligonucleotides with the WT (WT ssODN) or PAM mutant (Mut ssODN) sequences. Experiments are presented as
mean 6 standard deviation of three independent experiments normalized to transfection efficiency measured by DsRed cotransfected plasmid for 293 cells,
and 6standard deviation of an experiment performed in triplicate for the iPS cells. Statistical significance was calculated by Student’s t test. ***p! 0.001;
****p ! 0.0001.
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oligonucleotides, and, therefore, a plasmid donor was cho-
sen for correction of the CGD-causing mutation.
Gene editing of the endogenous CYBB gene locus using
the CRISPR-Cas9 system can reach clinically relevant
levels
With the aim being establishment of protocols for gene
therapy of CGD using the CRISPR-Cas9 system, we chose
to make use of the D10A-mutated version of Cas9, which is
only capable of cleaving a single strand of DNA [25]. By
providing two neighboring gRNAs, the Cas9D10A proteincan create a DSB, resulting in similar levels of homologous
recombination to the WT Cas9, but with the added advan-
tage of increasing the specificity of DSB formation and,
therefore, reducing off-target mutagenic events [25]. The
location of the gRNAs selected to target the CYBB gene
of iPS cells from patient CGD2 are shown in Figure 2A.
Note that one of the gRNA target sites contains the
disease-causing mutation within its PAM, which is not pre-
sent within the WT CYBB sequence; our intention was to
improve the efficiency of gene editing as seen in the fluo-
rescent reporter model. Using these conditions, gene editing
at the CYBB locus was detected at frequency of 11%
Figure 2. Schematic representation of the CYBB gene correction protocol. (A) Genomic organization of the first three exons of CYBB with consensus splice
donor (GT), splice acceptor (AG) and polypyrimidine tract (10-12Y) shown for each intron. An enhanced view showing the relevant segment of the intron 1/
exon 2 boundary is also shown to highlight the location of the CGD2 patient’s TO G mutation within the polypyrimidine tract and the location of the two
CRISPR-gRNA target sites (gp912 and gp913, underlined), along with their respective PAMs (bold). (B) Induced pluripotent stem cells generated from
patient CGD2 were grown under feeder free conditions, electroporated with CRISPR-gRNA constructs and repair template, and selected for transfected cells
using puromycin. The residual heterogeneous population of cells was assayed for gene-editing frequency by sequencing and was subsequently passaged onto
MEF feeder cells. Single-cell clones were picked, grown on MEFs, and assayed individually for their sequence at the CYBB gene. Successfully modified
clones were expanded, converted to feeder-free culture, assayed for pluripotency and intact karyotype, and differentiated into monocytes/macrophages using
an embryoid-body-based protocol [15]. Monocytes harvested from the factory supernatant, and subsequently M-CSF-differentiated macrophages, were then
assayed for phenotypic correction of the CGD mutation.
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signal intensities of the mixed chromatograms of the
sequencing reaction (Supplementary Figure E1, online
only, available at www.exphem.org).
Single cell clones, generated from CGD2.GC16A cells,
were sequenced for their CYBB identity (Supplementary
Figure E2, online only, available at www.exphem.org). Of
the 60 isolated clones, 14 (23%) were correctly modified,
containing the WT sequence at the intron/exon boundary,
21 (35%) contained insertion or deletion mutations at the
site of CRISPR-Cas9 cleavage, and 18 (30%) were unaf-
fected by the treatment. Thus, in agreement with our fluo-
rescent model, levels of gene conversion that have the
potential to be clinically relevant were obtained using
CRISPR-Cas9 gene editing at the CYBB locus. Two clones
(C4 and E4) were expanded and assayed for pluripotency(Supplementary Figures E3A and E3B, online only, avail-
able at www.exphem.org) and karyotypic abnormalities
(Supplementary Figure E3C, online only, available at
www.exphem.org) to ensure that the procedure had not
adversely affected their potential to generate phagocytic
cells and to serve as isogenic cell lines for the parental
unmodified CGD2 cell line.
Gene correction results in recovery of ROS activity
To demonstrate phenotypic correction at the CYBB locus,
as well as genotypic correction, the iPS cells were differen-
tiated into monocytes using an embryoid body-based proto-
col developed in our laboratory [15,26]. As was observed
previously [12], NADPH-oxidase-positive and -negative
lines all differentiated with similar efficiency, and mono-
cyte factories from all cell lines produced nonadherent
Figure 3. Correction of CYBB provides CGD2 iPS-derived myeloid cells with the ability to produce ROS. (A) Monocytes, (B) macrophages from WT
NHDF1 iPS cells (WT), a P47Phox mutant iPS cell line (CGD1), a CYBB mutant iPS cell line (CGD2), the mixed pool CGD2.GC16A of gene-edited iPS
cells (GC16A), and the two gene-edited single-cell clones from CGD2.GC16A (C4 and E4) were stimulated with PMA or with PMA and fMLP, respectively,
in the presence of NBT for 1 hour. Following exposure, the cells were washed in phosphate-buffered saline and fixed. Brightfield images were taken of cells
not exposed to the stimulant or the NBT (Neg), cells exposed to the NBT but without stimulation (UnStim), and cells exposed to both NBT and stimulant
(Stim). Images are representative of two independent experiments. (C) Macrophages were incubated for an additional 1 hour with the NBT and stimulant to
show the very low residual level of ROS production within the parental CGD2 cell line. Active ROS production can be seen by the precipitations of dark
ROS-mediated reduced NBT. Images were taken on an EVOS inverted microscope; scale bar 5 100 mm.
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mined by flow cytometry (Supplementary Figure E3D, on-
line only, available at www.exphem.org). To act as controls
for subsequent experiments, alongside the CGD2 cell lines
and its derivatives, monocytes were differentiated from WT
iPS cells as well as from a CGD patient (CGD1) with amutation in the P47Phox subunit of the NADPH oxidase
complex, which completely abolishes ROS production [12].
Three different assays for the generation of ROS activity
were performed on the iPS-derived myeloid cells. Firstly, a
qualitative assay for ROS, the NBT assay, was carried out
on monocytes adhered to tissue culture-treated plastic for
Figure 4. Quantification of ROS in CYBB-gene-corrected cell lines, as detected by DHR assay. (A) Monocytes and (B) macrophages from WT NHDF1 iPS
cells (WT), a P47Phox mutant iPS cell line (CGD1), a CYBB mutant iPS cell line (CGD2), the mixed pool CGD2.GC16A of gene edited iPS cells (GC16A),
and the two gene-edited single-cell clones from CGD2.GC16A (C4 and E4) were stimulated with PMA or with PMA and fMLP, respectively, for 30 min in
the presence of DHR, then immediately analyzed by flow cytometry (BD FACSCaliber). ROS generation is detected by oxidation of DHR into a fluorescent
product and quantified as fold change (top right of each panel) in mean fluorescence intensity of DHR fluorescence (dark grey) compared with the unstimu-
lated cells (light grey). Results shown are representative of two independent experiments.
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into macrophages for 7 days in M-CSF-containing medium
(Fig. 3B). The NBT assay relies on the reduction of the
soluble yellow NBT substrate into a colored precipitate
by the action of ROS. Wild-type cells were able to generate
ROS upon stimulation, whereas the negative control line,
CGD1, was not (Figs. 3A and 3B). As expected, phagocytic
cells from the CGD2 cell line appeared negative for ROS by
the NBT assay. The mixed population of gene-edited cells,
CGD2.GC16A, showed cells staining positive for ROS, and
the single-cell clones (CGD2.GC16A.C4 and CGD2.
GC16A.E4) derived from CGD2.GC16A all stained posi-
tive, showing highly effective phenotypic correction of
the ROS defect in cells derived from the CGD patient. As
noticed previously [12], a very low level of residual
NADPH oxidase activity is present in CGD2 cells, which
only becomes apparent upon extended incubation of the
cells with the NBT reagent for an additional hour (Fig. 3C).
For a quantitative assessment of the restoration of ROS
activity, monocytes and macrophages were assayed using
a DHR assay. This fluorescence-based assay relies on
ROS converting the nonfluorescent DHR reagent into fluo-
rescent rhodamine123b, providing a more quantitative
measure of ROS production. As with the NBT assay,
CGD1 and CGD2 cells showed little to no ROS production,
whereas WT cells showed a dramatic shift in fluorescence
upon stimulation (Fig. 4). The corrected single-cell clones,
CGD2.GC16A.C4 and CGD2.GC16A.E4, phenocopy the
WT cells both as monocytes and macrophages, and, as
expected, the mixed population CGD2.GC16A has interme-diate ROS levels. The lack of definition between positive
and negative cells in CGD2.GC16A cells results from the
very low levels of ROS activity in CGD2 cells (seen in
both the NBT and DHR assays) and possible transfer of
the ROS hydrogen peroxide from gene-edited cells to
parental cells; addition of catalase to breakdown hydrogen
peroxide minimizes, but does not completely remove, this
effect [27].
Finally, to provide kinetic information about ROS gener-
ation, a real-time luminol assay was performed on the
monocytes. Upon oxidation of the luminol reagent by
ROS, light is released, which can be measured within a
minute after addition of the cell stimulant PMA. As with
the previous results, CGD1 and CGD2 showed no produc-
tion of ROS upon stimulation, whereas clonal cells
CGD2.GC16A.C4 and CGD2.GC16A.E4 showed similar
quantities and kinetic properties to WT cells (max:
WT 5 169.5, C4 5 112.4, E4 5 147.4; slope:
WT 5 13.7, C4 5 12.96, E4 5 11.85; and time to reach
50% total signal: WT 5 62.7 sec, C4 5 59.6 sec,
E4 5 53.6 sec; sigmoidal curve fit) after the addition of
PMA, and the mixed population CGD2.GC16A had lower
levels but similar kinetics (max 5 29.6, slope 5 13.3,
time to reach 50% total signal 5 67.6 sec; Fig. 5).
Lack of ROS in CGD2 cells is due to exon skipping,
resulting in the absence of a functional protein
The cause of the ROS defect within CGD2 cells has not, to
our knowledge, been previously investigated, so we took
advantage of the isogenic properties of clones C4 and E4,
Figure 5. The kinetics of ROS production recapitulates WT cells after gene correction of CYBB in the CGD2 cell line. Monocytes from WT NHDF1 iPS
cells (WT), a P47Phox mutant iPS cell line (CGD1), a CYBB mutant iPS cell line (CGD2), the mixed pool CGD2.GC16A of gene-edited iPS cells (GC16A),
and the two gene-edited single-cell clones from CGD2.GC16A (C4 and E4) were exposed to luminol reagent in the presence (black line) or absence (grey
line) of PMA stimulation, and individual wells were monitored for light released at 1 sec intervals for 300 sec in triplicate using a PHERAstar FS (BMG
Labtech). The mean of three wells were normalized to the average of the 5 sec before luminol addition and are plotted with smoothing for clarity (average of
four neighboring data points). Results shown are representative of three independent experiments.
845R. Flynn et al./ Experimental Hematology 2015;43:838–848which are genetically and phenotypically WT at the CYBB
locus but within the genetic background of CGD2 cells, and
we measured the levels of CYBB mRNA and protein in
monocytes. Quantification of mRNA using primers located
within exon 1 and exon 3 showed similar levels of CYBB
mRNA across all cell lines, with CGD2 cells having a
slight, yet significant, reduction (Fig. 6A). However, when
using primers specific to the splice junctions of exons 1,
2, and 3, a more dramatic, hundredfold reduction in
CYBB message in CGD2 cells was observed (Fig. 6A).
These data indicate that, although CYBB mRNA is pro-
duced within CGD2 cells, it is incorrectly spliced. A
splicing defect was confirmed by running the product of
the exon 1 and exon 3 primers on a gel to observe the am-
plicon length compared with its predicted size (Fig. 6B).
Correct splicing of the CYBB mRNA produces a product
of 254 bp as observed (and confirmed by sequencing) in
WT, CGD1, and the fully corrected CGD2.GC16A.C4
and CGD2.GC16A.E4 clones (Fig. 6C). In CGD2 cells,
the WT product was not detected; instead, a smaller product
of 158 bp was obtained, corresponding to an exon-2-
skipped variant, the identity of which was confirmed by
sequencing (Fig. 6C). The mixed population CGD2.GC16A
showed both the exon-2-skipped variant band as well as a
faint WT band from the corrected mRNA. An additional
larger species, detected in CGD2, more pronounced in
CGD2.GC16A, but absent in all other reactions, was found
to be an artefact of the PCR reaction of a mixed population
(in CGD2, 1% of the CYBB mRNA are correctly splicedaccording to the qRT-PCR results with splicing-specific
primers in Fig. 6A). The CYBB protein is an integral mem-
brane protein with six transmembrane domains, and the
deletion of exon 2 results in the removal of half of the first
transmembrane domain and the neighboring loop (Fig. 7),
which is likely to lead to an incorrectly folded protein sus-
ceptible to endoplasmic reticulum (ER)-associated degra-
dation or a nonfunctional, possibly topologically-altered
protein.Discussion
Even in the era of potent antibiotics and fungicides, the
diagnosis of CGD implies lifelong health complications
and a reduced life expectancy [22]. In this article, we
have demonstrated the ability of the CRISPR-Cas9 system
to provide a footprintless strategy to correct a CGD-causing
mutation at potentially therapeutically useful levels. This
serves as a proof-of-principle in the development of genet-
ically clean gene therapy approaches to cure this mono-
genic inherited disease.
We have shown here that the CRISPR-Cas9 system has
the potential to provide highly efficient gene editing at the
CYBB locus. This type of phenotypic correction is prefer-
able to previous attempts to introduce the WT copy of
the gene into iPS cells using lentiviral vectors [28] because
it is completely clean; no residual foreign exogenous DNA
remains to contaminate the genome and cause insertional
mutagenesis, a hallmark problem with viral insertions.
Figure 6. A single point mutation in the 30 splice site of CYBB results in
exon skipping. (A) RNA levels of CYBB from monocytes from WT
NHDF1 iPS cells (WT), a P47Phox mutant iPS cell line (CGD1), a
CYBB mutant iPS cell line (CGD2), the mixed pool CGD2.GC16A of
gene-edited iPS cells (GC16A), and the two gene-edited single-cell clones
from CGD2.GC16A (C4 and E4) were measured by qRT-PCR with two
primer sets: one pair in which the primers bind the spliced junctions of
exon 1-2 and exon 2-3 (Exon 2) and one splicing independent pair that
binds exon 1 and exon 3 (Exon 1-3). Results are calculated relative to
b-actin internal control primer pair, normalized to the WT cell line, and
represent the average6 SEM of three independent cell harvests. Statistical
significance was calculated by two-way analysis of variance with Sidak’s
multiple comparison test. ***p! 0.001; ****p! 0.0001. (B) Schematic
representation of the CYBB mRNA pre- and postsplicing events producing
either the correct splicing pattern (WT) or potential exon-2-skipped variant
(Exon2-); the sizes of amplicon expected with primers binding exon 1 and
exon 3 are shown. (C) qRT-PCR products using primers in exon 1 and exon
3 on cDNA from monocytes were separated on an agarose gel. Major
bands corresponding to correctly spliced (WT) and the exon-skipped
variant (Exon2-) are marked with an arrow. Larger bands in CGD2 and
CGD2.GC16A (marked with an asterisk) were PCR artefacts.
Figure 7. Location of exon 2 of CYBB when inserted into the membrane.
Schematic representation of the CYBB protein within a membrane; the
region encoded by exon 2 that would be lost due to exon skipping is high-
lighted in black. Adapted from Marques et al. [49], based on Taylor et al.
[50].
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therefore, correctly controlled. This has been a major limi-
tation to lentiviral introduction of exogenous transgenes,
which either quickly become silenced or are not truly
expressed in a cell-specific manner, despite numerous
attempts to obtain specificity [29–31]. The limitation of
nonendogenous control is also true of the recently pub-
lished gene therapy strategies for CGD using zinc finger
nucleases targeting the AAVS1 safe harbor site for transgene
insertion in iPS cells, in which WT copies of the mutant
genes are constitutively expressed and, therefore, not
myeloid-specific [28,32,33]. Targeting the causative muta-
tion within the endogenous locus using scarless, or foot-printless, gene editing is, therefore, the ideal gene therapy
approach. Since high gene-targeting efficiencies are now
possible with the help of site-specific nucleases, it just
remains to transition this technology into clinically relevant
cells for its potential to be fully realized. Although here we
show correction of a single-point mutation that causes
CGD, there are numerous mutations within the CYBB
gene, as well as within the CYBA, NCF1, NCF2 and
NCF4 genes, that are also responsible for CGD in different
patients. Therefore, the strategy outlined here will require
tailoring specific gRNA pairs and donor templates for
each patient. It is worth noting that some genetic alterations
within these genes may not lend themselves to CRISPR-
Cas9 targeting (e.g., LINE1-retrotransposition) [34].
There are two methods that can be envisioned to exploit
this technology therapeutically. The most tractable approach
would be to convert the experimental protocol outlined in
this article to hematopoietic stem cells (HSCs) isolated
from bone marrow [35]. The technical limitations for such
an approach would be the efficiency of gene editing in the
HSCs and maintaining the bone-marrow-reconstituting po-
tential of these fragile cells ex vivo throughout the transfec-
tion, expansion, and selection procedures. Alternatively, a
technological advancement could allow for the creation of
authentic bone-marrow-repopulating HSCs from iPS cells
[36–38]. This would complete the circle of personalized
medicine: patient-derived iPS cells for gene editing, expan-
sion, and selection, differentiated into HSCs for reintroduc-
tion into the patient to repopulate the hematopoietic system
with disease-free cells. Such a procedure, although theoret-
ically possible, currently has multiple practical, safety, and
ethical issues. Most importantly, the karyotypic stability of
the cells would need to be very closely monitored. This be-
comes acutely obvious as more publications demonstrate
847R. Flynn et al./ Experimental Hematology 2015;43:838–848the potential for stem cells in culture to accumulate muta-
tions and karyotypic abnormalities over time [39–43].
Indeed, although the two single-cell clones isolated in this
study were grossly karyotypically normal at the resolution
of single nucleotide polymorphism (SNP) densities, this
does not provide genome-wide sequencing levels of
coverage [40,44], and a third clone from CGD2.GC16A
that was karyotyped during the course of this study had an
isochromosome 12p, a chromosome that has previously
been seen to enhance the proliferation of stem cells in cul-
ture when duplicated [43]. Additionally, off-target effects
of the CRISPR-Cas9 system are a potential issue, particu-
larly if the cells are intended for clinical use. Although
Cas9 uses complementarity between the gRNA and the
target DNA to determine cleavage site selection, specificity
is not absolute [45,46]. It was for this reason that we opted to
use the nicking version of Cas9, which minimizes this issue
[25,47]; however, clinical use may still require full genome
sequencing to ensure the genetic integrity of the cells after
gene correction.
Although neither of the potential clinical approaches
outlined above is currently practicable, it is worth noting
that site-specific nucleases have already been used
ex vivo to modify T cells in clinical trials for human immu-
nodeficiency virus (HIV), with no negative side effects
[48]. Thus, further work is merited to transfer this technol-
ogy into primary hematopoietic stem cells. Finally, a
greater understanding of human hematopoiesis is necessary
to generate repopulating HSCs ex vivo and thereby make
personalized gene therapy a reality.Acknowledgments
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Supplementary Figure E1. The heterogeneous pool of CRISPR-gRNA–transfected cells shows high levels of gene editing at the CYBB locus. Different
ratios of WT and mutant plasmids were sequenced: (A) 100% WT, (B) 40:60 WT/mutant, and (C) 100% mutant. (D) This provided a standard curve of signal
intensities at the T/G mutation site and allowed an estimate of the efficiency of gene conversion within a heterogeneous pool of gene-converted cells. The
location of the GO T mutation is highlighted in (A), along with the polypyrimidine tract (underlined) and the splice site (inverted triangle). WT5 wild type.
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Supplementary Figure E2. Sequence analysis of single-cell clones derived from the heterogeneous pool of gene-converted cells shows gene editing to be a
frequent event. The CYBB loci of 60 single-cell clones were aligned to the parental cell line CGD2 (shown at the top with PAM sites circled and an arrow
indicating the G O T mutation). Deletions induced by non-homologous end joining (NHEJ) following the CRISPR-gRNA–directed DSB are shown with
dashes.
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Supplementary Figure E3. Gene-edited single-cell clones maintain pluripotent marker expression, maintain a normal karyotype, and are able to produce
monocytes. iPS cells were stained for the pluripotent markers (A) TRA-1-60 (1.5 mg/mL; Biolegend) and (B) NANOG (0.3 mg/mL; Cell Signaling Tech-
nologies). Histogram plots are shown with antibody staining (dark gray) compared with their respective isotype controls (light gray); inset is the fold change
in mean fluorescent intensity (MFI) of antibody to isotype. Also shown are negative control cells (MEFs). Cell labeling was quantified by flow cytometry on a
BD FACSCalibur. (C) DNA extracted from the iPS cells was karyotyped using a SNP array (Illumina OmniExpress24 chip coveringw700,000 markers) and
analyzed using KaryoStudio (Illumina) to detect copy number variations across the genome. Red indicates a single copy of the SNPs (demonstrated by the
single X copy in this male patient’s DNA); gray indicates loss of heterozygosity; and green indicates duplications of a stretch of DNA (none present). (D)
Cells harvested from the monocyte factories were stained for CD14 (Immunotools) to ensure that they were of the monocyte/macrophage lineage. Histograms
from one harvest of cells are shown, indicating the percentage of live cells positive for CD14 (shown on gate) based on an unstained wild-type monocyte
population (light gray).
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